DUBLIN, Ohio, Nov. 9, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its SmartGown™ EDGE Breathable Surgical Gown with ASSIST™ Instrument Pockets, created to provide surgical teams safe and convenient instrument access in the operating room. Exclusively available from Cardinal Health, the gown is designed to hold one recommended instrument per pocket during surgical procedures, helping to provide handling efficiency and enabling clinical teams to focus on delivering safe patient care.
SmartGown™ EDGE is made with chest pockets that can keep frequently used surgical instruments* within easy reach while surgeons and clinicians operate across complex sterile fields. The gown's unique pocketed design helps minimize potential contamination and unintentional instrument drops outside the sterile area. With SmartGown™ EDGE, surgical teams can store repeatedly used instruments* in the gown's pockets helping to reduce instrument handoffs or exchanges during a procedure, while promoting potential time savings and self-sufficiency.
The creation of SmartGown™ EDGE is a result of a collaboration with Cardinal Health, Mayo Clinic and co-inventors Joseph Dearani, M.D., Director of Pediatric and Adult Congenital Heart Surgery and Salim Walji, M.D., retired Mayo Clinic cardiothoracic surgeon.
"Innovation is key to the success of Cardinal Health's portfolio and we're proud of our work with Mayo Clinic to develop the first pocketed surgical gown of its kind," said Kelley Moffett, senior vice president, Global Medical Products, Medical Segment, Cardinal Health. "Our customers and their patients are at the center of our decision making as we continue to invest and grow in key areas of our business to provide clinicians the solutions they need."
SmartGown™ is the leading brand of Association for the Advancement of Medical Instrumentation (AAMI) level 4 surgical gowns in the U.S.,1 providing the highest barrier of protection against liquid and viral penetration. As the newest addition to the SmartGown™ portfolio, SmartGown™ EDGE is rated AAMI level 4 protection with the ability to resist high fluid exposure and blood-borne pathogens and is designed with unique breathable technology to keep surgical staff cool and comfortable.
"Surgical teams are tasked to move quickly and expertly. Any deviations that prevent a smooth surgery, such as delays in instrument sterility or accessibility during the procedure, could create setbacks to the staff," said Dr. Dearani. "We're pleased to have developed a solution that helps minimize these operating room challenges and allows surgeons to keep procedures moving efficiently."
For more information on SmartGown™ EDGE Breathable Surgical Gown with ASSIST™ Instrument Pockets, please visit us here.
*Sharp, hot, heavy or long instruments should not be placed in pockets or holster |
1 Clarivate 2022 data analysis |
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research. |
About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.
Contacts: Brittany Julian, This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$119.14 |
Daily Change: | -0.06 -0.05 |
Daily Volume: | 654,573 |
Market Cap: | US$28.830B |
November 20, 2024 November 11, 2024 November 01, 2024 October 29, 2024 September 20, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB